Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laena Pernomian has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hypertension Drives Protein Lactylation and Vascular Dysfunction in Skeletal Muscle

    by Milene T. Fontes, Paul Townsend, Landon Butler, Juliana M. Parente, Fênix A. Araujo, Tiago J. Costa, Gisele F. Bomfim, Laena Pernomian, Wenbin Tan, Brandon N. VanderVeen, et al.

    BACKGROUND: Emerging evidence suggests a critical interplay between skeletal muscle metabolism and vascular function in the context of hypertension. Elevated plasma lactate levels precede the onset of hypertension and are inversely associated with skeletal muscle mass, highlighting skeletal muscle atrophy and metabolic dysregulation as key contributors to cardiovascular dysfunction. METHODS: Male and female Wistar rats and spontaneously hypertensive rats were studied. Skeletal muscle performance was evaluated using in vivo plantarflexion torque measurements. Femoral arteries with surrounding skeletal muscle were isolated to assess contractility and relaxation. Plasma and muscle lactate levels were quantified using colorimetric assays. Structural remodeling and mitochondrial function were assessed via wheat germ agglutinin staining, succinate dehydrogenase activity, and high-resolution respirometry. Protein lactylation was evaluated by mass spectrometry-based lactylated proteomics. Human translational relevance was examined using publicly available skeletal muscle transcriptomic data RESULTS: Spontaneously hypertensive rats exhibited skeletal muscle dysfunction marked by increased fatigability, reduced muscle mass, impaired mitochondrial activity, and elevated muscle lactate levels. Despite upregulation of oxidative markers, persistent lactate accumulation suggested a maladaptive metabolic shift. Proteomics revealed differential lactylation of key structural proteins (myosins, nebulin) and metabolic enzymes (Nampt, GAPDH [glyceraldehyde-3-phosphate dehydrogenase]). The anticontractile effect of skeletal muscle on femoral arteries was completely lost in spontaneously hypertensive rats, accompanied by impaired vascular relaxation and increased arterial lactylation. Human transcriptomic data supported parallel metabolic alterations in hypertension. CONCLUSIONS: Hypertension disrupts skeletal muscle metabolic homeostasis and muscle-vascular communication, driven in part by persistent lactate accumulation and altered protein lactylation. Targeting lactate-mediated signaling may offer new therapeutic avenues for hypertensive vascular dysfunction.

  • Open Access

    Editorial: Phenotypic transitions and endothelial dysfunction in cardiovascular diseases: mechanisms, therapeutic targets, and modulation

    by Laena Pernomian, Vanessa de Fátima Borges, Gerson Jhonatan Rodrigues, Cristina Espinosa-Diez

    The vascular system is essential for organ function and tissue homeostasis, with endothelial cells regulating vascular tone, permeability, angiogenesis, and blood interactions.Disruption of this balance causes endothelial dysfunction, a central driver of cardiovascular and metabolic diseases. This is aggravated by maladaptive phenotypic transitions, particularly endothelial-to-mesenchymal transition (EndMT), which, though beneficial in repair, promotes fibrosis, remodeling, and plaque instability when dysregulated, contributing to atherosclerosis, diabetes, and hypertension (Kovacic et al., 2019). Understanding these transitions remains a challenge. This Research Topic explores the interplay between endothelial dysfunction and vascular cell phenotypes in disease progression (Figure 1).Within the context of atherosclerosis, endothelial dysfunction represents an initiating and central event, as highlighted by Yang et al., who offer an integrative perspective bridging traditional pharmacotherapy with emerging novel therapeutic approaches. Their review emphasizes how endothelial and vascular cell phenotypic changes drive the disease process, through EndMT-derived fibroblast accumulation (Brokopp et al., 2011), extracellular matrix deposition and inflammation (Cheng et al., 2015), and vascular smooth muscle cell (VSMC) switching (Chappell et al., 2016). Yang et al. illustrate how targeting maladaptive cell states through statins, renin-angiotensin system inhibitors, microRNAs, and reprogramming strategies may represent a paradigm shift for long-term vascular health.A similar emphasis on endothelial dysfunction is evident in the context of diabetes.Here, Liu et al. expand on the multifactorial pathways, including oxidative stress, insulin resistance, and chronic hyperglycemia, that converge to impair endothelial cell function (Shah, Brownlee, 2016). By showing how these stressors reduce nitric oxide bioavailability, disrupt intercellular junctions, and trigger epigenetic modifications, their review underscores the endothelial cell as the primary target of diabetic vascular damage. Importantly, they also highlight how therapeutic strategies, including compounds from traditional Chinese medicine, may help preserve or restore endothelial function, positioning these cells as central targets for reducing cardiovascular risk in diabetes. (Moschetti et al., 2022;Cecere et al., 2024), further reinforcing the idea that vascular pathology emerges from a convergence of endothelial injury, phenotypic transitions, and immune activation.These studies illustrate the role of endothelial dysfunction and vascular cell phenotypic transitions in a wide spectrum of cardiovascular diseases. Endothelial cells, along with phenotypically plastic of vascular cells, constitute both key drivers of vascular injury and promising therapeutic targets. These findings highlight the importance of moving beyond symptom control to strategies that restore vascular homeostasis by correcting dysfunctional cellular states, thereby opening the door to transformative therapies for cardiovascular diseases.

  • Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of EndMT in Hypertensive Mice

    by Laena Pernomian, Emily W. Waigi, Vi Nguyen, Ahmed D. Mohammed, Tiago J. Costa, Milene T. Fontes, Jason L. Kubinak, Andrew V. Aitken, Vinicia Campana Biancardi, Kamryn Gleason, et al.

    BACKGROUND: Small artery remodeling and endothelial dysfunction are hallmarks of hypertension. Evidence supports a likely causal association between cardiovascular diseases and endothelial-to-mesenchymal transition (EndMT), a cellular transdifferentiation process in which endothelial cells (ECs) partially lose their identity and acquire mesenchymal phenotypes. EC reprogramming represents an innovative strategy in regenerative medicine to prevent deleterious effects induced by cardiovascular diseases. METHODS: Using partial reprogramming of ECs, via overexpression of Oct-3/4-Sox-2-Klf-4 (OSK) transcription factors, we aimed to bring ECs back to a youthful phenotype in hypertension. Primary ECs were infected with lentiviral vectors (LVs) containing the specific EC promoter Cdh5 (cadherin-5) and the reporter EGFP (enhanced green fluorescent protein) with empty vector (LV control) or LV with Oct-3/4-Sox-2-Klf-4. Confocal microscopy and Western blotting analysis were used to confirm OSK overexpression. Cellular migration, senescence, and apoptosis were evaluated. Human aortic ECs from normotensive patients and patients with hypertension were analyzed after OSK treatments for eNOS (endothelial nitric oxide synthase), nitric oxide (NO), and genetic profile. Male and female normotensive (BPN/3J or blood pressure normal mouse strain) and hypertensive (BPH/2J or blood pressure high mouse strain) mice were treated with LV control or LV with Oct-3/4-Sox-2-Klf-4 and evaluated 10 days post-infection. The blood pressure, cardiac function, vascular reactivity of small arteries, and EndMT inhibition were analyzed. RESULTS: OSK overexpression induced partial EC reprogramming in vitro, and these cells had lower migratory capability. OSK treatment of BPH/2J mice reduced blood pressure and resistance arteries hypercontractility, via the attenuation of endothelial-to-mesenchymal transition and elastin breaks. EGFP was detected in vivo in the prefrontal cortex. OSK-treated hypertensive human aortic ECs showed high eNOS activation and NO production, with low reactive oxygen species (ROS) formation. Single-cell RNA analysis showed that OSK alleviated EC senescence and EndMT, restoring their phenotypes in human aortic ECs from patients with hypertension. CONCLUSIONS: Overall, these data indicate that OSK treatment and EC reprogramming can decrease blood pressure and reverse hypertension–induced vascular damage.


  • Open Access

    Single-vessel transcriptome map pathological landscapes and reveal NR2F2-mediated smooth muscle cell phenotype acquisition in capillary malformations

    by Vi Nguyen, Irving Mao, Siwuxie He, Isabella Castellanos, Mackenzie Azuero, Marcelo L Hochman, Yin Rong, Laena Pernomian, Elliott H Chen, Harold I Friedman, et al.

    Summary: Background: Capillary malformation (CM) is a congenital vascular anomaly affecting the skin, mucosa, and brain, yet the understanding of its vascular pathogenesis remains limited. Methods: We applied spatial whole-transcriptome profiling (GeoMx) and gene set enrichment analysis within CM lesions at single vasculature level. Differentially expressed genes were validated by immunofluorescence staining. Phosphoproteomics was profiled to uncover lesion- wide phosphorylation sites on proteins. Single-cell RNA sequencing was performed on CM- derived induced pluripotent stem cells (iPSCs) to determine differentiation trajectories of lesional vascular lineages. In silico gene perturbation was used to predict candidate genes for modulating vascular pathological progression, followed by functional validation in CM iPSC-derived endothelial cells (ECs) using a Tet-on system. Results: A spatial transcriptomic atlas was constructed, and pathological landscape of individual CM vasculature was delineated. CM vessels exhibited hallmarks of endothelial-to-mesenchymal transition (EndMT), including disruption of adherens junctions (AJs), vascular identity transitions, and metabolic remodeling. Phosphoproteomics confirmed that differentially phosphorylated proteins were enriched in EndMT- and AJ-related pathways. Aberrant expression of venous transcriptional factor NR2F2 was observed in lesional ECs and correlated with progressive enlargement from capillaries to larger-caliber vessels containing multiple layers of smooth muscle cells (SMCs). In CM iPSCs, differentiation course yielded reduced ECs but increased SMCs. In silico knockout simulation predicted NR2F2 as a crucial regulator of facilitating SMC phenotype in CM. Consistently, enforced NR2F2 expression during iPSC differentiation suppressed endothelial markers while inducing SMC-associated genes. Conclusions: Single CM vasculature displays pathological hallmarks characterized by EndMT and AJ disruption, leading to progressive vascular remodeling. NR2F2 functions as a central regulatory factor orchestrating the acquisition of the SMC phenotype, thereby representing a potential therapeutic target in CM.


  • Hypertensive BPH/2J mice exhibit sex-specific heart failure progression and late-life microvascular rarefaction

    by Laena Pernomian, Emily W. Waigi, Juliana M. Parente, Cameron G. McCarthy, Camilla F. Wenceslau

    Male hypertensive BPH/2J mice develop characteristics of HFmrEF and cardiac microvascular rarefaction, whereas female hypertensive BPH/2J mice recapitulate features of HFpEF. SCa1+ cells in the heart might play a role in left ventricular ejection fraction (LVEF) worsening. Preventing the loss of cardiac EC can be a strategy to reduce fibrosis and stimulate angiogenesis to improve cardiac repair in HF.

  • Orphan Under Pressure: GPR146 as a Mechanotransduction Modulator

    by Laena Pernomian, Juliana Montenegro Parente, Cameron G. McCarthy, Camilla Ferreira Wenceslau


  • Open Access

    Tetrahydrocurcumin Outperforms Curcumin in Preventing Oxidative Stress-Induced Dysfunction in Tert-Butyl Hydroperoxide-Stimulated Cardiac Fibroblasts

    by Patrícia dos Santos Azeredo, Charity Fix, Laena Pernomian, Camilla F. Wenceslau, Gerardo G. Piroli, Cristina Pontes Vicente, Wayne E. Carver

    Oxidative stress is a common feature of various pathological conditions, including tissue remodeling and dysfunction. Cardiac fibroblasts, which play a key role in maintaining extracellular matrix homeostasis, are sensitive to oxidative injury. Curcumin and tetrahydrocurcumin are plant-derived polyphenols with antioxidant properties, yet their relative efficacy in preventing oxidative stress–induced dysfunction in cardiac fibroblasts remains unclear. In this study, cardiac fibroblasts were treated with curcumin or tetrahydrocurcumin prior to exposure to tert-butyl hydroperoxide (t-BHP), a widely used inducer of oxidative stress. Cell viability, apoptosis, reactive oxygen species (ROS) production, and Tgfb1 expression were assessed. Both curcuminoids significantly attenuated oxidative stress–induced cell death, decreased cell viability, and reduced Tgfb1 expression. Notably, tetrahydrocurcumin demonstrated superior protective effects across most parameters. These findings suggest that both compounds help mitigate oxidative-stress–induced cellular dysfunction in cardiac fibroblasts and highlight tetrahydrocurcumin as a potentially more effective antioxidant. Further studies are needed to explore their role in the context of tissue remodeling and fibrotic progression.


  • Open Access

    A Single-Short Partial Reprogramming of the Endothelial Cells decreases Blood Pressure via attenuation of EndMT in Hypertensive Mice

    by Laena Pernomian, Emily W. Waigi, Vi Nguyen, Ahmed D. Mohammed, Tiago J. da Costa, Milene T. Fontes, Jason L. Kubinak, Andrew Aitken, Vinicia Campana Biancardi, David A. Sinclair, et al.

    Background: Small artery remodeling and endothelial dysfunction are hallmarks of hypertension. Growing evidence supports a likely causal association between cardiovascular diseases and the presence of endothelial-to-mesenchymal transition (EndMT), a cellular transdifferentiation process in which endothelial cells (ECs) partially lose their identity and acquire additional mesenchymal phenotypes. EC reprogramming represents an innovative strategy in regenerative medicine to prevent deleterious effects induced by cardiovascular diseases. Methods: Using a partial reprogramming of ECs, via overexpression of Oct-3/4, Sox-2, and Klf-4 (OSK) transcription factors, we aimed to bring ECs back to a youthful phenotype in hypertensive mice. Primary ECs were infected with lentiviral vectors (LV) containing the specific EC marker cadherin 5 (Cdh5) and the fluorescent reporter enhanced green fluorescence protein (EGFP) with empty vector (LVCO) or with OSK (LV-OSK). Confocal microscopy and western blotting analysis were used to confirm the OSK overexpression. Cellular migration, senescence, and apoptosis were evaluated. Human aortic ECs (HAoECs) from male and female normotensive and hypertensive patients were analyzed after OSK or control treatments for their endothelial nitric oxide synthase (eNOS) levels, nitric oxide (NO), and genetic profile. Male and female normotensive (BPN/3J) and hypertensive (BPH/2J) mice were treated with an intravenous (i.v.) injection of LVCO or LV-OSK and evaluated 10 days post-infection. The blood pressure, cardiac function, vascular reactivity of small arteries, in vivo EGFP signal and EndMT inhibition were analyzed. Results: OSK overexpression induced partial EC reprogramming in vitro , and these cells showed endothelial progenitor cell (EPC)-like features with lower migratory capability. OSK treatment of hypertensive BPH/2J mice normalized blood pressure and resistance arteries hypercontractility, via the attenuation of EndMT and elastin breaks. EGFP signal was detected in vivo in the prefrontal cortex of both BPN/3J and BPH/2J-treated mice, but OSK induced angiogenesis only in male BPN/3J mice. OSK-treated human ECs from hypertensive patients showed high eNOS activation and NO production, with low ROS formation. Single-cell RNA analysis showed that OSK alleviated EC senescence and EndMT, restoring their phenotypes in human ECs from hypertensive patients. Conclusion: Overall, these data indicate that OSK treatment and EC reprogramming can decrease blood pressure and reverse hypertension-induced vascular damage.


  • Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents

    by Ana P.S. Gaspari, Roberto Santana da Silva, Zumira A. Carneiro, Marcelo Rodrigues de Carvalho, Ivone Carvalho, Laena Pernomian, Lucimara P. Ferreira, Loyanne C.B. Ramos, Gabriel Aguiar de Souza, André L.B. Formiga

    Background: Several metal-based molecules that display cytotoxicity against multiple cell lines have been pursued in an attempt to fight against cancer and to overcome the typical side effects of drugs like cisplatin. In this scenario, ruthenium complexes have been extensively studied due to their activity in both in vitro and in vivo biological systems, including various cancer cell strains. Objective: We aimed to develop a method to synthesize novel [Ru(NO)(bpy)2L2]2+ complexes containing amino acid ligands by using an alternative Click Chemistry approach, namely the copper azide-alkyne cycloaddition reaction (CuAAC reaction), to construct nitrosyl/nitrite complexes bearing a modified lysine residue. Methods: We synthesized a new ligand by Click Chemistry approach and new compounds bearing the unprecedented ligand. Cytotoxicity was assessed by the classical MTT colorimetric assay. MCF-7 and MDAMB- 231 cells were used as breast cancer cell models. MCF-10 was used as a model of healthy cells. Results: Amino acid ligands related to N3-Lys(Fmoc) and the new pyLys were successfully synthesized by the diazotransfer reaction and the CuAAC reaction, respectively. The latter reaction involves coupling between N3-Lys(Fmoc) and 3ethynylpyridine. Both N3-Lys(Fmoc) and the new pyLys were introduced into the ruthenium bipyridine complex I, or cis-[RuII(NO)(NO2)(bpy)2]2+, to generate the common nitro-based complex III, which was further converted to the final complex IV. Results of the MTT assay proved the cytotoxic effect of cis- [RuII(NO)(pyLysO-)(bpy)2](PF6)2 against the mammalian breast cancer cells MCF-7 and MDA-MB231. Conclusion: The viability assays revealed that complex IV, bearing a NO group and a modified lysine residue, was able to release NO and cross tumor cell membranes. In this work, Complex IV was observed to be the most active ruthenium bipyridine complex against the mammalian breast cancer cells MCF-7 and MDA-MB231: it was approximately twice as active as cisplatin, whilst complexes I-III proved to be less cytotoxic than complex IV. Additional tests using healthy MCF 10A cells showed that complexes II-IV were three- to sixfold less toxic than cisplatin, which suggested that complex IV was selective against cancer cells.